Sumitomo Mitsui Trust Group
RNAM

Sumitomo Mitsui Trust Group’s Avidity Biosciences RNAM Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,755
Closed -$338K – 1087
2025
Q3 		$338K Buy
+7,755
New +$314K ﹤0.01% 999

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sumitomo Mitsui Trust Group's RNAM Position: Q4 2025 in Review

Sumitomo Mitsui Trust Group sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 7,755 shares — an estimated $338K sold.

Sumitomo Mitsui Trust Group first reported a position in RNAM in Q3 2025 and held it in 1 quarter. The position peaked at $338K in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • Sumitomo Mitsui Trust Group reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • Sumitomo Mitsui Trust Group sold 7,755 Avidity Biosciences shares in Q4 2025, an estimated $338K.
  • Sumitomo Mitsui Trust Group first reported a position in Avidity Biosciences in Q3 2025 and held it in 1 quarter.
  • Sumitomo Mitsui Trust Group's Avidity Biosciences position peaked at $338K in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q4 2025, filed 23 Jan 2026.